BioCentury | Sep 21, 1998
Company News

Cytogen cancer, diagnostics/imaging news

...CYTO ceased operations at its Cellcor Inc. subsidiary, which was developing its autologous lymphocyte therapy (ALT) to...
...carcinoma. CYTO had been in discussions concerning either a management buyout or other sale of Cellcor...
...BioCentury, March 30). CYTO reduced its workforce by 37 employees, including the 23 involved in Cellcor...
BioCentury | Aug 3, 1998
Company News

Cytogen cancer, diagnostics/imaging news

...its Cellcor Inc. subsidiary have fallen through and CYTO's board is considering a proposed buyout of Cellcor...
BioCentury | Mar 30, 1998
Company News

Cytogen cancer, diagnostics/imaging news

...under development by CYTO's Cellcor Inc. subsidiary, until a partner for the program can be found. Cellcor...
...also is considering selling Cellcor, which it acquired in 1995 (see BioCentury, Oct. 23, 1995). Cellcor...
...was spending $5 million per year. CYTO's burn rate is $1.1 million per month, including Cellcor's...
BioCentury | Jan 26, 1998
Company News

Cytogen board of directors update

...who relinquished his positions as CYTO's chairman, president and CEO to become president of CYTO's Cellcor Inc....
BioCentury | Jan 26, 1998
Company News

Cytogen management update

...who relinquished his positions as CYTO's chairman, president and CEO to become president of CYTO's Cellcor Inc....
BioCentury | Dec 23, 1996
Company News

Cytogen, Neoprobe deal

...CYTO's Cellcor subsidiary (Newton, Mass.) will manufacture RIGS/ACT, NEOP's activated cell therapy product to treat metastatic...
...Newton, Mass.) will manufacture RIGS/ACT, NEOP's activated cell therapy product to treat metastatic colorectal cancer. Cellcor...
...front fee and will record contract revenue on a per patient basis. NEOP will use Cellcor's...
BioCentury | Jun 10, 1996
Company News

Cytogen, Neoprobe deal

...product using the cell processing and development manufacturing facility in Needham, Mass., operated by CYTO's Cellcor...
BioCentury | Oct 23, 1995
Company News

Cellcor, Cytogen deal

...Aug. 17 purchased $20 million of CYTO (Princeton, N.J.) common stock at $3.89 (see Offerings). Cellcor Inc....
BioCentury | Sep 25, 1995
Clinical News

Autolymphocyte therapy: To start patient accrual in the fourth quarter under a Treatment IND in patients with stage IV disease who did not participate in the co

...CLTX is in the process of merging with CYTOGEN Corp. (Princeton, N.J.) (see page B2). Cellcor Inc....
BioCentury | Sep 25, 1995
Company News

Cytogen, Cellcor deal

...committed to the purchase of at least $12 million of the offering. CYTOGEN Corp. (CYTO) Cellcor Inc....
Items per page:
1 - 10 of 23
BioCentury | Sep 21, 1998
Company News

Cytogen cancer, diagnostics/imaging news

...CYTO ceased operations at its Cellcor Inc. subsidiary, which was developing its autologous lymphocyte therapy (ALT) to...
...carcinoma. CYTO had been in discussions concerning either a management buyout or other sale of Cellcor...
...BioCentury, March 30). CYTO reduced its workforce by 37 employees, including the 23 involved in Cellcor...
BioCentury | Aug 3, 1998
Company News

Cytogen cancer, diagnostics/imaging news

...its Cellcor Inc. subsidiary have fallen through and CYTO's board is considering a proposed buyout of Cellcor...
BioCentury | Mar 30, 1998
Company News

Cytogen cancer, diagnostics/imaging news

...under development by CYTO's Cellcor Inc. subsidiary, until a partner for the program can be found. Cellcor...
...also is considering selling Cellcor, which it acquired in 1995 (see BioCentury, Oct. 23, 1995). Cellcor...
...was spending $5 million per year. CYTO's burn rate is $1.1 million per month, including Cellcor's...
BioCentury | Jan 26, 1998
Company News

Cytogen board of directors update

...who relinquished his positions as CYTO's chairman, president and CEO to become president of CYTO's Cellcor Inc....
BioCentury | Jan 26, 1998
Company News

Cytogen management update

...who relinquished his positions as CYTO's chairman, president and CEO to become president of CYTO's Cellcor Inc....
BioCentury | Dec 23, 1996
Company News

Cytogen, Neoprobe deal

...CYTO's Cellcor subsidiary (Newton, Mass.) will manufacture RIGS/ACT, NEOP's activated cell therapy product to treat metastatic...
...Newton, Mass.) will manufacture RIGS/ACT, NEOP's activated cell therapy product to treat metastatic colorectal cancer. Cellcor...
...front fee and will record contract revenue on a per patient basis. NEOP will use Cellcor's...
BioCentury | Jun 10, 1996
Company News

Cytogen, Neoprobe deal

...product using the cell processing and development manufacturing facility in Needham, Mass., operated by CYTO's Cellcor...
BioCentury | Oct 23, 1995
Company News

Cellcor, Cytogen deal

...Aug. 17 purchased $20 million of CYTO (Princeton, N.J.) common stock at $3.89 (see Offerings). Cellcor Inc....
BioCentury | Sep 25, 1995
Clinical News

Autolymphocyte therapy: To start patient accrual in the fourth quarter under a Treatment IND in patients with stage IV disease who did not participate in the co

...CLTX is in the process of merging with CYTOGEN Corp. (Princeton, N.J.) (see page B2). Cellcor Inc....
BioCentury | Sep 25, 1995
Company News

Cytogen, Cellcor deal

...committed to the purchase of at least $12 million of the offering. CYTOGEN Corp. (CYTO) Cellcor Inc....
Items per page:
1 - 10 of 23